Fig. 1.

Predictive markers are needed to adequately select those patients benefiting from DSB-inducing agents (such as bifunctional alkylators, platinum salts, or PARPi) out of the general breast or ovarian cancer populations. In general, three ways of predictive marker studies can be distinguished. Examples are given for all three options (in example 2, aCGH plots are depicted, with on the x-axis the chromosomes, and on the y-axis the log2-ratio of tumor DNA over normal DNA). IHC immunohistochemistry, CNA copy number aberration, HR homologous recombination, hrs hours, DSB double-strand break